OBJECTIVE: To determine the clinical efficacy and safety of Liangxue Jiedu decoction(LJD) for the treatment of progressive psoriasis vulgaris and to provide the basis for the development of a standardized treatment pr...OBJECTIVE: To determine the clinical efficacy and safety of Liangxue Jiedu decoction(LJD) for the treatment of progressive psoriasis vulgaris and to provide the basis for the development of a standardized treatment protocol for psoriasis vulgaris.METHODS: In this multicenter, randomized, controlled study, patients with blood-heat type psoriasis were randomly assigned to receive either Chinese herbal medicine(LJD;treatment group) or Western Medicine(cetirizine hydrochloride, vitamin C, and vitamin B complex;control group). Psoriasis Area and Severity Index(PASI) scores were calculated in addition to the number of patients who achieved ≥ 50% or ≥ 75% improvement in PASI score from baseline. The change in symptoms of Chinese medicine(color of rash, burning sensation,itchiness, severity of irritation, and anger) was evaluated and safety was assessed as adverse events and laboratory analysis. t test, independent sample non-parametric test and χ2 test were used to analyze the results.RESULTS: A total of 238 participants were included in the study [treatment group, n = 122(PP analysis117);control group, n = 116(PP analysis 104)]. LJD treatment was associated with a significant improvement in skin lesions and symptoms com-pared with Western Medicine treatment. At the end of the 8-week treatment period, 23.77%(PP analysis 24.79%) of patients in the treatment group had achieved PASI75 and 57.38%(PP analysis 58.97%)had achieved PASI50;the corresponding figures in the control group were 9.48%(9.62%) and 25.00%(25.00%), respectively. The between-group differences were statistically significant(P < 0.05).CONCLUSION: Treatment of psoriasis vulgaris of the blood-heat type using LJD was associated with significantly better outcomes compared with those achieved using standard Western Medicine.展开更多
目的:观察清肝凉血解毒方(QGLXJD)、凉血活血方(LXHX)对咪喹莫特诱导的银屑病样小鼠行为学及神经肽Y(NPY)表达的影响。方法:30只BALB/c雄性小鼠,剔除背部毛发,随机分为空白对照组(C)、模型组(M)、清肝凉血解毒方组(QG)、凉血活血方组(LX...目的:观察清肝凉血解毒方(QGLXJD)、凉血活血方(LXHX)对咪喹莫特诱导的银屑病样小鼠行为学及神经肽Y(NPY)表达的影响。方法:30只BALB/c雄性小鼠,剔除背部毛发,随机分为空白对照组(C)、模型组(M)、清肝凉血解毒方组(QG)、凉血活血方组(LX)和甲氨蝶呤组(MTX)。背部涂抹5%咪喹莫特乳膏(IMQ)诱导皮肤银屑病样模型。采用银屑病皮损面积和疾病严重程度(Psoriasis area and severity index,PASI)每日进行评分,分别运用旷场及高架十字迷宫评价各组小鼠行为学差异,HE染色后光镜下测量表皮厚度;免疫组化法检测皮损中T淋巴细胞表面标志CD3+及表皮中增殖细胞核抗原(PCNA)表达情况;采用实时PCR技术检测皮损中IL-23、IL-1β、IL-12 mRNA表达水平;Western blot法检测皮损中NPY蛋白表达情况。结果:与C组相比,M组表皮厚度、PCNA、CD3+T细胞、IL-1β、IL-12、IL-23 mRNA表达均增加(P<0.05);其余组与M组相比,表皮薄,PCNA、CD3+T细胞、IL-1β、IL-12、IL-23 mRNA表达水平均降低(P<0.05)。与C组比较,银屑病样小鼠焦虑水平高,以M组最为明显;QG组与M组比较,焦虑水平低,而LX组与QG组比较,焦虑水平高;NPY在M组中表达最多,在LX、QG、C组表达依次减少。结论:清肝凉血解毒方能改善银屑病样小鼠的焦虑行为,下调NPY的表达水平,从整体角度改善小鼠银屑病样皮损。展开更多
目的评价凉血解毒汤治疗血热型寻常型银屑病的临床疗效和安全性。方法将30例血热型寻常型银屑病患者,给予口服凉血解毒汤（生槐花、紫草、赤芍、白茅根等）治疗6周,通过观察记录患者治疗前后受累体表面积（body surface area,BSA）和病...目的评价凉血解毒汤治疗血热型寻常型银屑病的临床疗效和安全性。方法将30例血热型寻常型银屑病患者,给予口服凉血解毒汤（生槐花、紫草、赤芍、白茅根等）治疗6周,通过观察记录患者治疗前后受累体表面积（body surface area,BSA）和病情严重程度指数（psoriasis area and severity index,PASI）评分以及皮肤病生活质量指数（dermatology life quality index,DLQI）评分,进行疗效评定;通过检测治疗前后患者血尿常规,肝肾功、心电图进行安全性评估。结果治疗后BSA和PASI评分较治疗前均有不同程度下降,差异具有统计学意义（P〈0.05）,患者DLQI评分较治疗前降低,且差异具有统计学意义（P〈0.05）。治疗总有效率为93.3%,无明显的不良反应。结论凉血解毒汤治疗血热型寻常型银屑病具有较好疗效,且安全性良好。展开更多
目的:观察自拟凉血解毒汤治疗中老年寻常型银屑病的临床疗效及对血清白介素水平的影响。方法:将所有就诊于我院皮肤科的银屑病患者共80例,随机分为治疗组与对照组两组,每组各40例。所有患者均接受一般治疗,对照组予阿维A胶囊口服,25 mg/...目的:观察自拟凉血解毒汤治疗中老年寻常型银屑病的临床疗效及对血清白介素水平的影响。方法:将所有就诊于我院皮肤科的银屑病患者共80例,随机分为治疗组与对照组两组,每组各40例。所有患者均接受一般治疗,对照组予阿维A胶囊口服,25 mg/次,2次/d。治疗组予自拟中药凉血解毒汤口服。每日1剂,水煎服,每次100 m L,每日3次。2组疗程均为2个月,疗程结束后观察疗效。结果:2组治疗后临床疗效比较,治疗组的有效率为77.5%,对照组的有效率为55.0%,2组相比,有统计学差异(P<0.05)。在2组治疗前后PASI评分及症状严重程度评分比较中,治疗组治疗后的积分明显高于对照组治疗后的积分,2组相比,有统计学差异(P<0.05)。在2组治疗前后IL-8水平比较中,治疗组治疗后的IL-8水平明显低于对照组治疗后水平,2组相比,有统计学差异(P<0.05)。结论:口服自拟中药凉血解毒汤治疗中老年寻常型银屑病,可以明显提高临床疗效,改善患者临床症状及病程严重程度,并且有效的降低血清中IL-8的水平,且无明显毒副作用,疗效明显优于对照组,值得临床推广使用。展开更多
基金Supported by the National Natural Science Foundation Project(No.81673975:Study on the Mechanism of Hui Yang Sheng Ji Gao Promoting Ulcer Angiogenesis in Type 2 Diabetes Mellitus and No.81774309:Study on the Immune Regulation Mechanism of PI3K/Akt/m TOR Signaling Pathway Mediated by tlrs-4 in Light Sensitive Skin Diseases by Clearing Heat,Cooling Blood and Detoxification)the Beijing Science and Technology Commission Funded Project(No.Z161100000516108:a Randomized Controlled Clinical Study on the Indications of TCM External Treatment for Psoriasis with"Analogic Drug Selection"and No.Z161100001816024:Research and Development of Traditional Chinese Medicine Preparation for Treatment of Sunburn By Hao Qin Huaban Granule)。
文摘OBJECTIVE: To determine the clinical efficacy and safety of Liangxue Jiedu decoction(LJD) for the treatment of progressive psoriasis vulgaris and to provide the basis for the development of a standardized treatment protocol for psoriasis vulgaris.METHODS: In this multicenter, randomized, controlled study, patients with blood-heat type psoriasis were randomly assigned to receive either Chinese herbal medicine(LJD;treatment group) or Western Medicine(cetirizine hydrochloride, vitamin C, and vitamin B complex;control group). Psoriasis Area and Severity Index(PASI) scores were calculated in addition to the number of patients who achieved ≥ 50% or ≥ 75% improvement in PASI score from baseline. The change in symptoms of Chinese medicine(color of rash, burning sensation,itchiness, severity of irritation, and anger) was evaluated and safety was assessed as adverse events and laboratory analysis. t test, independent sample non-parametric test and χ2 test were used to analyze the results.RESULTS: A total of 238 participants were included in the study [treatment group, n = 122(PP analysis117);control group, n = 116(PP analysis 104)]. LJD treatment was associated with a significant improvement in skin lesions and symptoms com-pared with Western Medicine treatment. At the end of the 8-week treatment period, 23.77%(PP analysis 24.79%) of patients in the treatment group had achieved PASI75 and 57.38%(PP analysis 58.97%)had achieved PASI50;the corresponding figures in the control group were 9.48%(9.62%) and 25.00%(25.00%), respectively. The between-group differences were statistically significant(P < 0.05).CONCLUSION: Treatment of psoriasis vulgaris of the blood-heat type using LJD was associated with significantly better outcomes compared with those achieved using standard Western Medicine.
文摘目的:观察清肝凉血解毒方(QGLXJD)、凉血活血方(LXHX)对咪喹莫特诱导的银屑病样小鼠行为学及神经肽Y(NPY)表达的影响。方法:30只BALB/c雄性小鼠,剔除背部毛发,随机分为空白对照组(C)、模型组(M)、清肝凉血解毒方组(QG)、凉血活血方组(LX)和甲氨蝶呤组(MTX)。背部涂抹5%咪喹莫特乳膏(IMQ)诱导皮肤银屑病样模型。采用银屑病皮损面积和疾病严重程度(Psoriasis area and severity index,PASI)每日进行评分,分别运用旷场及高架十字迷宫评价各组小鼠行为学差异,HE染色后光镜下测量表皮厚度;免疫组化法检测皮损中T淋巴细胞表面标志CD3+及表皮中增殖细胞核抗原(PCNA)表达情况;采用实时PCR技术检测皮损中IL-23、IL-1β、IL-12 mRNA表达水平;Western blot法检测皮损中NPY蛋白表达情况。结果:与C组相比,M组表皮厚度、PCNA、CD3+T细胞、IL-1β、IL-12、IL-23 mRNA表达均增加(P<0.05);其余组与M组相比,表皮薄,PCNA、CD3+T细胞、IL-1β、IL-12、IL-23 mRNA表达水平均降低(P<0.05)。与C组比较,银屑病样小鼠焦虑水平高,以M组最为明显;QG组与M组比较,焦虑水平低,而LX组与QG组比较,焦虑水平高;NPY在M组中表达最多,在LX、QG、C组表达依次减少。结论:清肝凉血解毒方能改善银屑病样小鼠的焦虑行为,下调NPY的表达水平,从整体角度改善小鼠银屑病样皮损。
文摘目的评价凉血解毒汤治疗血热型寻常型银屑病的临床疗效和安全性。方法将30例血热型寻常型银屑病患者,给予口服凉血解毒汤（生槐花、紫草、赤芍、白茅根等）治疗6周,通过观察记录患者治疗前后受累体表面积（body surface area,BSA）和病情严重程度指数（psoriasis area and severity index,PASI）评分以及皮肤病生活质量指数（dermatology life quality index,DLQI）评分,进行疗效评定;通过检测治疗前后患者血尿常规,肝肾功、心电图进行安全性评估。结果治疗后BSA和PASI评分较治疗前均有不同程度下降,差异具有统计学意义（P〈0.05）,患者DLQI评分较治疗前降低,且差异具有统计学意义（P〈0.05）。治疗总有效率为93.3%,无明显的不良反应。结论凉血解毒汤治疗血热型寻常型银屑病具有较好疗效,且安全性良好。
文摘目的:观察自拟凉血解毒汤治疗中老年寻常型银屑病的临床疗效及对血清白介素水平的影响。方法:将所有就诊于我院皮肤科的银屑病患者共80例,随机分为治疗组与对照组两组,每组各40例。所有患者均接受一般治疗,对照组予阿维A胶囊口服,25 mg/次,2次/d。治疗组予自拟中药凉血解毒汤口服。每日1剂,水煎服,每次100 m L,每日3次。2组疗程均为2个月,疗程结束后观察疗效。结果:2组治疗后临床疗效比较,治疗组的有效率为77.5%,对照组的有效率为55.0%,2组相比,有统计学差异(P<0.05)。在2组治疗前后PASI评分及症状严重程度评分比较中,治疗组治疗后的积分明显高于对照组治疗后的积分,2组相比,有统计学差异(P<0.05)。在2组治疗前后IL-8水平比较中,治疗组治疗后的IL-8水平明显低于对照组治疗后水平,2组相比,有统计学差异(P<0.05)。结论:口服自拟中药凉血解毒汤治疗中老年寻常型银屑病,可以明显提高临床疗效,改善患者临床症状及病程严重程度,并且有效的降低血清中IL-8的水平,且无明显毒副作用,疗效明显优于对照组,值得临床推广使用。
